The influence of relapse rate on the choice of duodenal ulcer therapy.
D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000191:economics; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D012008:Recurrence; D012907:Smoking / Q000009:adverse effects; D013392:Sucralfate / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D013392:Sucralfate; C002791:bismuth tripotassium dicitrate